Thrombophilia Panel 5

Service Description

PCR-hybridization: This test uses to detect 12 genetic variations associated with increased risk of thrombosis and cardiovascular disease. These are: - Factor ΙΙ (G20210A) - Factor V (G1691A, R2 H1299A) - MTHFR(C677T,Α1298C) - Factor ΧΙΙ (V34L) - PAI-1 - ApoB - ApoE - ΑCE - GPIIIa - Fibrinogen-β Factor II and Factor V are both clotting factors that are involved in the formation of blood clots. Genetic variations in these genes, including G20210A and G1691A, have been associated with an increased risk of thrombosis, including deep vein thrombosis (DVT) and pulmonary embolism (PE). MTHFR is an enzyme involved in the metabolism of homocysteine. Genetic variations in the MTHFR gene, including C677T and Α1298C, have been associated with an increased risk of thrombosis, as well as other conditions such as stroke and birth defects. Factor XII is a clotting factor that is involved in the coagulation cascade. Genetic variations in the Factor XII gene, including V34L, have been associated with an increased risk of thrombosis. PAI-1 is a protein involved in the regulation of blood clotting. Genetic variations in the PAI-1 gene have been associated with an increased risk of thrombosis and cardiovascular disease. ApoB and ApoE are both proteins involved in the transport of lipids, including cholesterol. Genetic variations in these genes have been associated with an increased risk of atherosclerosis and cardiovascular disease. ACE is an enzyme involved in the renin-angiotensin-aldosterone system, which regulates blood pressure and fluid balance. Genetic variations in the ACE gene have been associated with an increased risk of hypertension and cardiovascular disease. GPIIIa is a glycoprotein involved in platelet aggregation and clot formation. Genetic variations in the GPIIIa gene have been associated with an increased risk of cardiovascular disease, particularly in individuals with diabetes. Fibrinogen-β is a protein involved in the coagulation process. Genetic variations in the Fibrinogen-β gene have been associated with an increased risk of cardiovascular disease, particularly in individuals with diabetes. Sample: BLOOD Results:2 weeks Phlebotomy fee: £15 (included in price)